drugset / Trial / NCT04637269
Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are few effective treatments for MM(multiple myeloma). BCMA (B cell maturation antigen) is a promising target for malignant plasma cells. Therefore, we designed a clinical trial using anti-BCMA CAR-T cell therapy for patients with relapsed and refractory multiple myeloma.
Timeline
- Start
- 2020-11-17
- Primary completion
- 2021-11-01
- Completion
- 2023-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-BCMA CAR-T | Cell therapy | 5e+07 cells/kg | — |
| Subject | anti-BCMA CAR-T | Cell therapy | 1.5e+08 cells/kg | — |
| Subject | anti-BCMA CAR-T | Cell therapy | 4.5e+08 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |